Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v2.3.0.15
Condensed Balance Sheets (USD $)
Sep. 30, 2011
Dec. 31, 2010
Assets:    
Cash and cash equivalents $ 13,216,933 $ 12,340,239
Marketable securities (note 4) 1,950,000 2,451,620
Research tax credit receivable 0 145,513
Prepaid expenses and other current assets (note 5) 455,709 706,649
Note receivable - current portion (note 6) 25,688 28,023
Total Current Assets 15,648,330 15,672,044
Restricted Cash Equivalents (note 18) 2,947,451 401,893
Note receivable (note 6) 0 18,682
Equipment, Net (note 7) 93,072 123,565
Total Assets 18,688,853 16,216,184
Liabilities:    
Accounts payable and accrued expenses (note 8) 3,905,460 1,820,900
Deferred Research and Development Arrangement (note 9) 843,750 900,000
Other Liabilities (note 10) 113,640 133,117
Warrant Liabilities (note 15) 3,653,706 2,966,710
Total Liabilities 8,516,556 5,820,727
Commitments and Contingencies (note 18)    
Stockholders' Equity (note 13):    
Preferred stock, par value $0.0001, 100,000,000 authorized shares, none issued and outstanding 0 0
Common stock, par value $0.0001, 500,000,000 authorized shares, 95,279,861 (2010 - 84,175,504) issued and outstanding 95,265,656 (2010 - 84,160,849) 9,528 8,418
Additional paid-in capital 67,665,073 56,157,452
Accumulated other comprehensive loss 0 (2,340)
Accumulated deficit during the development stage (57,473,894) (45,739,663)
Treasury stock, 14,205 shares, at cost (28,410) (28,410)
Total Stockholders' Equity 10,172,297 10,395,457
Total Liabilities and Stockholders' Equity $ 18,688,853 $ 16,216,184